- Why are Traders Bullish on This Food Company?
- Profiting From Natural Gas: Strategists
- 3 Hot Mid-Cap Stock Picks: Portfolio Manager
- 'Nice Opportunities' in Health Care Sector: Stock Picker
- Stocks To Play With Health Reform: Analysts
- 4 Tech Stocks For This Holiday Season: Analyst
- Art Cashin: I'm Still Skeptical About Markets
- Rockwell Automation Earnings: What Options Are Saying
- Gold Will Touch Higher Lows and Higher Highs: Analyst
- Correction Coming When Fed Ends 'Easy Money': Market Pro
MOST SHARED
- Obama Sees Strains Unless US, China Balance Growth
- Future of Marketing
- Can Apple Top Microsoft as Most Valuable Tech Firm?
- European Commission Objects to Sun Micro-Oracle Deal
- Mad Mail: Buy the Berkshire Hathaway Split?
- Priceline Crushes Profit Forecasts; Shares Jump
- Oil Tomorrow
- Sprint to Cut Up to 2,500 Jobs, Sees Charge
- Cramer: 5 Stocks to Play the Next Bull Run
- GM CEO Starts Opel Charm Tour in Germany
- Why Google is Paying $750 Million for Ad Mob
- Warren Buffett to Sell Stakes In Union Pacific & Norfolk Southern
- Nov. 9: Unusual Volume Leaders
- The Battered Businesses Behind Housing
- Modern Warfare 2's Record-Breaking Launch
- Merck’s Mega-Monday Morning
- Why are Traders Bullish on This Food Company?
- Profiting From Natural Gas: Strategists
- S&P Stocks Trading at New 52-Week Highs
- Fed's Tarullo Backs Surcharges to Limit Bank Size
- Look Ahead: 'Risk On' Sentiment Could Fuel Rally Further
- European Commission Objects to Sun Micro-Oracle Deal
- Obama Sees Strains Unless US, China Balance Growth
- JPMorgan Lifts Salary Freeze Amid Recovery
- Can Apple Top Microsoft as Most Valuable Tech Firm?
- Do You Know Your Coca-Cola Myths?
- Buffett to Sell Stakes in Norfolk Southern, Union Pacific
- Cramer: 5 Stocks to Play the Next Bull Run
RSS FEED
CNBC Stock Blog
Will Muggia likes biotech. Muggia's Touchstone Mid-Cap Growth Fund is up an average of 14.9 percent annually over the last three years -- and even this year, it's up 1.8 percent. So what are the 4-star portfolio manager's picks?
Recommendations:
Muggia likes Celgene [CELG
Loading...
()
], "one of the fastest-growing biotechnology companies in the world today. He expects the firm to have 40 percent earnings growth.
He praises Elan Pharmaceuticals [ELAN
Loading...
()
] for its auto-immune and Alzheimer's medicines. He says the latter illness has barely begun to be addressed medically, with plenty of potential left.
CNBC.com Web Exclusive:
(Not found on TV)
For CNBC.com readers, Muggia also recommends Chesapeake Energy [CHK
Loading...
()
].
Disclosures:
Muggia personally owns both Celgene and Elan, and the stocks are the largest holdings in his fund.









